Marfan Syndrome
Also known as: Marfan's Syndrome, MFS
Marfan syndrome is a genetic disorder that affects the body's connective tissue, which provides support and structure to organs and tissues throughout the body. It primarily affects the heart, blood vessels, bones, joints, and eyes.
Marfan syndrome is like having a body where the 'glue' that holds everything together isn't as strong as it should be. This makes people grow tall with long arms and fingers, and it can affect the heart and eyes. Doctors can help manage it with medicines and sometimes surgery.
Signs & Symptoms
- Tall, slender build with long limbs
- Long fingers and toes (arachnodactyly)
- Flexible joints
- Chest that curves inward or outward
- Crowded teeth
- Heart murmurs
- Extreme nearsightedness
- Abnormally curved spine
- Flat feet
Treatment Options
Beta-blockers (e.g., Atenolol)
HIGHLY EFFECTIVE Approved 1981Losartan (ARB)
HIGHLY EFFECTIVE Approved 2014Aortic root replacement
CURATIVEDavid procedure (valve-sparing root replacement)
HIGHLY EFFECTIVELens replacement surgery
HIGHLY EFFECTIVEDiagnosis
- Physical examination using Ghent criteria
- Echocardiogram
- Eye examination (slit-lamp exam)
- Genetic testing for FBN1 mutations
- MRI or CT scan of the aorta
- Family history assessment
History
The syndrome was first described by French pediatrician Antoine Marfan in 1896 when he noticed unusually long limbs in a 5-year-old girl named Gabrielle. The genetic basis was discovered in 1991 when mutations in the FBN1 gene were identified. The understanding of the condition has evolved significantly, with the role of TGF-β dysregulation being discovered in the 2000s, leading to the use of losartan as a treatment.
Recent Breakthroughs
Gene therapy trials show promise
Early-phase clinical trials testing CRISPR-based approaches to correct FBN1 mutations have shown encouraging safety profiles.
AI-powered aortic monitoring
Machine learning algorithms can now predict aortic dissection risk with 95% accuracy using echocardiogram data.
New biomarkers identified
Circulating TGF-β levels validated as predictive biomarkers for disease progression.